Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 4
Submit an article Journal homepage
283
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment

Romain Gounota Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France;b Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France
,
Fabien Le Brasa Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France
,
Jehan Dupuisa Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France
,
Silvia Oghinab Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France;c Referral Center for Cardiac Amyloidosis and Cardiology Department, Hopital Henri Mondor, APHP, Créteil, France
,
Diane Bodezb Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France;c Referral Center for Cardiac Amyloidosis and Cardiology Department, Hopital Henri Mondor, APHP, Créteil, France
,
Louise Roulina Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France;b Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France
,
Alizee Maareka Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France;b Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France
,
Amandine Ladaiqueb Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France;d Pharmacy Unit, Hopital Henri Mondor, APHP, Créteil, France
,
Asma Beldi-Ferchioub Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France;e Immunology Laboratory, Hopital Henri Mondor, APHP, Créteil, France
,
Elsa Poullotf Département de Pathologie, Hôpital Henri Mondor, APHP, Créteil, France
,
Valerie Molinier-Frenkelb Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France;e Immunology Laboratory, Hopital Henri Mondor, APHP, Créteil, France
,
Corinne Haiouna Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France;b Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France
,
Thibaud Damyb Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, France;c Referral Center for Cardiac Amyloidosis and Cardiology Department, Hopital Henri Mondor, APHP, Créteil, France
,
Karim Belhadja Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France
&
François Lemonniera Hopital Henri Mondor, Unité hémopathies Lymphoïdes, APHP, Créteil, France;b Université Paris Est Créteil - Hopital Henri Mondor - Unité hémopathies Lymphoïdes - APHP, Créteil, FranceCorrespondence[email protected]
 show all
Pages 979-983 | Received 06 Nov 2020, Accepted 08 Jul 2020, Published online: 29 Nov 2020

References

  • Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757.
  • Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280.
  • Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427.
  • Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479–1485.
  • Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902.
  • Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33(2):531–536.
  • Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis. Br J Haematol. 2018;185(2):342–344.
  • Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase II study. Blood. 2020;135(18):1541–1547.
  • Roussel M, Stoppa A-M, Perrot A, et al. A prospective phase II of daratumumab in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2017;130:508.
  • Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.
  • Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria. Blood. 2020;135(18):1517–1530.
  • Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–328.
  • Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
  • Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842–848.
  • Palladini G, Milani P, Foli A, et al. A phase II trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–2123.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.